Conveglipron (HDM1002)
HDM1002 · Huadong Medicine
Oral GLP-1 receptor agonist under regulatory review for weight management in China.
Reported findings
Sponsor reports that the obesity Phase 3 primary endpoint was met.
Numerical Phase 3 results were not included in the interim report. An ADA 2026 Phase 2 abstract is available; U.S. obesity development has not been confirmed.
Source report ↗Mechanism at a glance
Obesity stage by formulation
Latest: Huadong reported that China’s National Medical Products Administration accepted the conveglipron tablet marketing application for weight management on November 2, 2026.
Next: China regulatory review and any confirmed development outside China.
Clinical study records
Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.
Obesity and weight-management studies
Phase 3 studies1 record
HDM1002 obesity Phase 3
Weight managementChina obesity study; sponsor reports the primary endpoint was met.
Phase 2 studies1 record
HDM1002 obesity Phase 2
Weight managementEarlier obesity study; Phase 2 results were presented at ADA 2026.
